Related Experiment Video
Updated: Aug 12, 2026
14:10
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Targeted Nanotechnology in Glioblastoma Multiforme
Talita Glaser1, Inbo Han2, Liquan Wu3
1Department of Biochemistry, Institute of Chemistry, University of São PauloSão Paulo, Brazil.
Frontiers in Pharmacology
|April 15, 2017
Summary
Targeting aggressive brain tumors like glioblastoma requires overcoming the blood-brain barrier and drug-resistant cancer stem cells (CSCs). Nanomedicine and gene-editing technologies offer promising strategies for more effective glioblastoma treatments.
Area of Science:
- Neuro-oncology
- Nanomedicine
- Cancer Biology
Background:
- Gliomas, especially glioblastoma multiforme, are aggressive brain tumors with poor prognosis and high recurrence rates.
- Current treatments (surgery, temozolomide chemotherapy, radiotherapy) show limited efficacy, with median survival under 15 months.
- The blood-brain barrier (BBB) restricts chemotherapy drug delivery, and cancer stem cells (CSCs) exhibit resistance to conventional therapies, contributing to treatment failure.
Purpose of the Study:
- To profile biological features and biomarkers of glioblastoma cancer stem cells (CSCs).
- To detail nanomedicine strategies targeting CSCs by circumventing the BBB.
- To analyze the gap between CSC biology and targeted therapy development for glioblastoma.
Main Methods:
- Review of nanomedicine approaches including organic and inorganic nanoparticles (e.g., liposomes, dendrimers, polymeric micelles).
- Analysis of gene expression manipulation strategies like small interfering RNA (siRNA) and CRISPR/Cas9.
- Profiling of CSC biomarkers and biological characteristics.
Main Results:
- Significant advancements in nanotherapies utilizing various nanoparticle formulations for targeted drug delivery.
- Exploration of novel gene-editing technologies for potential glioblastoma treatment.
- Identification of key CSC properties relevant to therapeutic targeting.
Conclusions:
- A deeper understanding of CSC biology is crucial for developing precise nanotherapies.
- Nanomedicine and gene-editing present viable avenues to overcome BBB and CSC resistance.
- Targeted therapeutic regimens are urgently needed to improve outcomes for glioblastoma patients.
